Intense Pulsed Light Therapy with Optimal Pulse Technology as an Adjunct Therapy for Moderate to Severe Blepharitis-Associated Keratoconjunctivitis
Table 2
Comparison of secondary outcome measures.
Items
Groups
V0
V1
V2
V3
V4
CFS score
Treatment group
6.02 ± 3.74
2.86 ± 2.83
2.52 ± 2.38
2.05 ± 2.23
0.67 ± 1.07
<0.001
Control group
6.14 ± 4.44
3.50 ± 2.82
3.82 ± 3.35
2.82 ± 2.92
1.14 ± 1.64
<0.001
0.915
0.391
0.078
0.243
0.173
NIKBUT
Treatment group
7.38 ± 5.79
7.44 ± 4.14
9.14 ± 4.97
10.71 ± 4.04
12.07 ± 4.14
<0.001
Control group
7.10 ± 5.61
7.17 ± 4.16
8.73 ± 4.95
9.23 ± 4.06
10.53 ± 4.48
0.085
0.857
0.803
0.759
0.168
0.175
OSDI score
Treatment group
35.38 ± 15.76
22.08 ± 12.94
16.03 ± 9.54
8.18 ± 8.01
6.89 ± 7.61
<0.001
Control group
44.76 ± 17.06
31.62 ± 15.89
22.32 ± 8.97
14.84 ± 7.32
12.05 ± 4.64
<0.001
0.130
0.077
0.081
0.029
0.049
SIT
Treatment group
7.31 ± 5.24
6.81 ± 4.49
7.93 ± 4.19
8.26 ± 3.91
8.93 ± 3.62
0.197
Control group
8.36 ± 5.17
5.91 ± 2.71
7.77 ± 2.74
7.64 ± 3.05
8.09 ± 3.31
0.168
0.445
0.393
0.875
0.516
0.370
Classification of tear film lipid layer
Treatment group
2.67 ± 0.85
2.93 ± 0.87
2.71 ± 0.80
2.64 ± 0.91
2.45 ± 0.83
0.155
Control group
2.86 ± 0.83
2.91 ± 0.75
2.59 ± 0.80
2.59 ± 0.67
2.45 ± 0.51
0.175
0.377
0.929
0.561
0.813
0.991
Meibomian gland dropout (upper eyelid)
Treatment group
2.14 ± 0.84
2.45 ± 0.63
2.60 ± 0.63
2.50 ± 0.63
2.38 ± 0.73
0.044
Control group
2.59 ± 0.67
2.45 ± 0.67
2.55 ± 0.51
2.55 ± 0.60
2.41 ± 0.59
0.857
0.035
0.990
0.750
0.782
0.877
Meibomian gland dropout (lower eyelid)
Treatment group
2.17 ± 0.82
2.45 ± 0.55
2.64 ± 0.62
2.48 ± 0.71
2.57 ± 0.59
0.016
Control group
2.82 ± 0.39
2.55 ± 0.51
2.73 ± 0.46
2.32 ± 0.72
2.68 ± 0.48
0.062
0.001
0.512
0.574
0.401
0.452
value of one-way repeated measure analysis of variance to compare data for each group at different time points; value of multivariate analysis to compare the treatment and control groups at a specific time point.
